Immunocore (IMCR) Competitors

$28.76 +0.39 (+1.38%)

As of 03:53 PM Eastern

IMCR vs. CNTA, SRRK, COGT, XENE, and APLS

Should you buy Immunocore stock or one of its competitors? MarketBeat compares Immunocore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunocore include Centessa Pharmaceuticals (CNTA), Scholar Rock (SRRK), Cogent Biosciences (COGT), Xenon Pharmaceuticals (XENE), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.

How does Immunocore compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Immunocore	-6.68%	-7.07%	-2.55%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Centessa Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	394.71	-$197.53M	-$1.79	N/A
Immunocore	$400.02M	3.65	-$35.51M	-$0.55	N/A

In the previous week, Immunocore had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 1 mentions for Immunocore and 0 mentions for Centessa Pharmaceuticals. Immunocore's average media sentiment score of 0.99 beat Centessa Pharmaceuticals' score of 0.07 indicating that Immunocore is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Immunocore	Positive

Centessa Pharmaceuticals presently has a consensus target price of $40.70, suggesting a potential upside of 2.58%. Immunocore has a consensus target price of $57.75, suggesting a potential upside of 100.45%. Given Immunocore's stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Immunocore beats Centessa Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Immunocore compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Scholar Rock has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Immunocore	-6.68%	-7.07%	-2.55%

In the previous week, Scholar Rock had 6 more articles in the media than Immunocore. MarketBeat recorded 7 mentions for Scholar Rock and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.99 beat Scholar Rock's score of 0.58 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential upside of 17.77%. Immunocore has a consensus target price of $57.75, suggesting a potential upside of 100.45%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Immunocore has higher revenue and earnings than Scholar Rock. Immunocore is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Immunocore	$400.02M	3.65	-$35.51M	-$0.55	N/A

Summary

Scholar Rock and Immunocore tied by winning 8 of the 16 factors compared between the two stocks.

How does Immunocore compare to Cogent Biosciences?

Immunocore (NASDAQ:IMCR) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Immunocore has higher revenue and earnings than Cogent Biosciences. Immunocore is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.65	-$35.51M	-$0.55	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Cogent Biosciences	N/A	-104.27%	-54.64%

Immunocore currently has a consensus price target of $57.75, suggesting a potential upside of 100.45%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 38.91%. Given Immunocore's higher possible upside, research analysts plainly believe Immunocore is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Immunocore had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 1 mentions for Immunocore and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.00 beat Immunocore's score of 0.99 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunocore	Positive
Cogent Biosciences	Positive

Summary

Immunocore beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Immunocore compare to Xenon Pharmaceuticals?

Immunocore (NASDAQ:IMCR) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Immunocore. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 1 mentions for Immunocore. Xenon Pharmaceuticals' average media sentiment score of 1.01 beat Immunocore's score of 0.99 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore has higher revenue and earnings than Xenon Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.65	-$35.51M	-$0.55	N/A
Xenon Pharmaceuticals	$7.50M	692.23	-$345.91M	-$4.70	N/A

Immunocore currently has a consensus target price of $57.75, suggesting a potential upside of 100.45%. Xenon Pharmaceuticals has a consensus target price of $77.07, suggesting a potential upside of 43.50%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Immunocore on 9 of the 17 factors compared between the two stocks.

How does Immunocore compare to Apellis Pharmaceuticals?

Immunocore (NASDAQ:IMCR) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Apellis Pharmaceuticals has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.65	-$35.51M	-$0.55	N/A
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23

84.5% of Immunocore shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Immunocore's net margin of -6.68%. Apellis Pharmaceuticals' return on equity of 39.71% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

In the previous week, Apellis Pharmaceuticals had 5 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for Apellis Pharmaceuticals and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.99 beat Apellis Pharmaceuticals' score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore presently has a consensus price target of $57.75, indicating a potential upside of 100.45%. Apellis Pharmaceuticals has a consensus price target of $35.72, indicating a potential downside of 12.94%. Given Immunocore's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunocore is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Summary

Apellis Pharmaceuticals beats Immunocore on 10 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.46B	$3.27B	$6.29B	$12.15B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-52.43	18.74	20.64	25.14
Price / Sales	3.65	281.73	580.02	91.94
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	3.83	6.61	9.75	6.65
Net Income	-$35.51M	$24.30M	$3.55B	$335.51M
7 Day Performance	-1.67%	-3.01%	-1.59%	-1.56%
1 Month Performance	-8.39%	-7.31%	-3.51%	-1.44%
1 Year Performance	-7.06%	53.03%	30.08%	28.08%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	3.3027 of 5 stars	$28.76 +1.4%	$57.75 +100.8%	-6.6%	$1.47B	$400.02M	N/A	320
CNTA Centessa Pharmaceuticals	1.9019 of 5 stars	$39.60 +0.0%	$40.70 +2.8%	+216.9%	$5.91B	N/A	N/A	200	Negative News
SRRK Scholar Rock	2.8102 of 5 stars	$49.11 +1.6%	$56.00 +14.0%	+55.1%	$5.88B	N/A	N/A	140
COGT Cogent Biosciences	3.1675 of 5 stars	$33.86 -0.7%	$43.73 +29.1%	+542.6%	$5.78B	N/A	N/A	80
XENE Xenon Pharmaceuticals	3.6353 of 5 stars	$55.65 -0.2%	$74.56 +34.0%	+77.3%	$5.37B	$7.50M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. CNTA, SRRK, COGT, XENE, and APLS

How does Immunocore compare to Centessa Pharmaceuticals?

Summary

How does Immunocore compare to Scholar Rock?

Summary

How does Immunocore compare to Cogent Biosciences?

Summary

How does Immunocore compare to Xenon Pharmaceuticals?

Summary

How does Immunocore compare to Apellis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. CNTA, SRRK, COGT, XENE, and APLS

How does Immunocore compare to Centessa Pharmaceuticals?

Is CNTA or IMCR more profitable?

Do insiders and institutionals hold more shares of CNTA or IMCR?

Which has more volatility & risk, CNTA or IMCR?

Which has higher earnings & valuation, CNTA or IMCR?

Does the media favor CNTA or IMCR?

Do analysts rate CNTA or IMCR?

Summary

How does Immunocore compare to Scholar Rock?

Do insiders & institutionals believe in SRRK or IMCR?

Which has more volatility and risk, SRRK or IMCR?

Is SRRK or IMCR more profitable?

Does the media prefer SRRK or IMCR?

Do analysts rate SRRK or IMCR?

Which has higher valuation and earnings, SRRK or IMCR?

Summary

How does Immunocore compare to Cogent Biosciences?

Which has higher earnings & valuation, IMCR or COGT?

Which has more volatility & risk, IMCR or COGT?

Do insiders and institutionals hold more shares of IMCR or COGT?

Is IMCR or COGT more profitable?

Do analysts rate IMCR or COGT?

Does the media refer more to IMCR or COGT?

Summary

How does Immunocore compare to Xenon Pharmaceuticals?

Is IMCR or XENE more profitable?

Does the media prefer IMCR or XENE?

Which has stronger valuation and earnings, IMCR or XENE?

Do analysts prefer IMCR or XENE?

Which has more risk & volatility, IMCR or XENE?

Do insiders & institutionals hold more shares of IMCR or XENE?

Summary

How does Immunocore compare to Apellis Pharmaceuticals?

Which has higher earnings and valuation, IMCR or APLS?

Do insiders & institutionals have more ownership in IMCR or APLS?

Is IMCR or APLS more profitable?

Which has more risk and volatility, IMCR or APLS?

Does the media prefer IMCR or APLS?

Do analysts recommend IMCR or APLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools